Liver health may change how body handles inhaled lung drug

NCT ID NCT07643155

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and measures drug levels in the blood over time. The goal is to understand if liver problems require dose adjustments, not to test the drug's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

treprostinil palmitil inhalation powder

What this could lead to

If successful, this study could help doctors determine safe dosing of treprostinil palmitil for people with liver problems.

What could go wrong

This is a small, early-phase trial focused on drug processing, not treatment effectiveness. Results may not apply to all patients or lead to changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••